Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

ABSTRACT:

Background

Camizestrant, the next-generation oral selective estrogen receptor degrader and complete estrogen receptor (ER) antagonist, has previously demonstrated superiority over fulvestrant in patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Capivasertib is a selective AKT inhibitor recommended with fulvestrant for patients with PIK3CA/AKT1/PTEN-altered ER-positive, HER2-negative advanced breast cancer. Here, we report data from Parts I and J of SERENA-1 (NCT03616587), evaluating the safety, tolerability, pharmacokinetics and efficacy for the combination of camizestrant and capivasertib.

Patients and methods

SERENA-1 is a phase I, open-label, multi-part trial of camizestrant alone and in combination with other anti

SUBMITTER: Vaklavas C 

PROVIDER: S-EPMC12861197 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature